New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection Induces Transforming Growth Factor β1 Production through Glucose-Regulated Protein 94 by Jee, M.H et al.
New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection
Induces Transforming Growth Factor 1 Production through Glucose-
Regulated Protein 94
Min Hyeok Jee,a Ka Young Hong,a Ji Hoon Park,a Jae Seung Lee,b Hee Sun Kim,b Song Hee Lee,a Sung Key Janga
POSTECH Biotech Center, Department of Life Sciences, Pohang University of Science and Technology, Pohang, Kyungbuk, Republic of Koreaa; Division of Integrative
Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang, Kyungbuk, Republic of Koreab
ABSTRACT
Hepatitis C virus (HCV) is one of the leading causes of chronic liver inflammatory disease (hepatitis), which often leads to more
severe diseases, such as liver fibrosis, cirrhosis, and hepatocellular carcinoma. Liver fibrosis, in particular, is a major pathogenic
consequence of HCV infection, and transforming growth factor 1 (TGF-1) plays a key role in its pathogenesis. Several HCV
proteins have been suggested to either augment or suppress the expression of TGF-1 by HCV-infected cells. Here, we report
that TGF-1 levels are elevated in HCV-infected hepatocytes cultured in vitro and in liver tissue of HCV patients. Notably, the
level of TGF-1 in media from in vitro-cultured HCV-infected hepatocytes was high enough to activate primary hepatic stellate
cells isolated from rats. This indicates that TGF-1 secreted by HCV-infected hepatocytes is likely to play a key role in the liver
fibrosis observed in HCV patients. Moreover, we showed that HCV E2 protein triggers the production of TGF-1 by HCV-in-
fected cells through overproduction of glucose-regulated protein 94 (GRP94).
IMPORTANCE
Hepatic fibrosis is a critical step in liver cirrhosis caused by hepatitis C virus infection. It is already known that immune cells,
including Kupffer cells, mediate liver fibrosis. Recently, several papers have suggested that HCV-infected hepatocytes also signif-
icantly produce TGF-1. Here, we provide the first examination of TGF-1 levels in the hepatocytes of HCV patients. Using an
HCV culture system, we showed that HCV infection increases TGF-1 production in hepatocytes. Furthermore, we confirmed
that the amount of TGF-1 secreted by HCV-infected hepatocytes was sufficient to activate primary hepatic stellate cells. To un-
derstand the molecular basis of TGF-1 production in HCV-infected hepatocytes, we used HCV replicons and various stable cell
lines. Finally, we elucidated that HCV E2 triggered TGF-1 secretion via GRP94mediated NF-B activation. This study contrib-
utes to the understanding of liver fibrosis by HCV and suggests a new potential target (GRP94) for blocking liver cirrhosis in
HCV patients.
Hepatitis C virus (HCV) is one of the leading causes of chronicinflammatory liver disease (hepatitis) (1). According to
World Health Organization reports, about 170 million people
currently suffer from HCV infection worldwide (2). Chronic
HCV infection often results in the development of hepatic fibro-
sis, cirrhosis, and hepatocellular carcinoma (HCC) (3).
HCV is a positive-sense, single-stranded RNA virus whose
9.6-kb genome encodes at least 10 viral proteins, including four
structural and six nonstructural proteins (4). Error-prone RNA-
dependent RNA polymerase (RDRP) generates a wide variety of
mutations (5), which complicates development of HCV vaccines
(6). Several therapeutic agents have recently been developed for
HCV-related chronic hepatitis, including direct-acting antivirals
(DAAs) that target HCV viral proteins (7, 8).
Liver fibrosis is known to be tightly linked with HCV infection
and ultimately leads to liver dysfunction and cirrhosis (9). Liver
fibrosis is involved in the process of healing wounds caused by
chronic inflammation (one of the prominent features of HCV
infection-related pathogenesis) and the death of HCV-infected
hepatocytes (10). In fibrotic states, liver tissue shows abnormal
accumulation of extracellular matrix (ECM) and changes in ECM
composition (11, 12).
Generally, liver fibrosis progression is promoted by activated
hepatic stellate cells (HSCs) (13). In the normal liver, HSCs reside
in the sinusoidal space in a quiescent state (14), but upon activa-
tion by cytokines, they secrete large amounts of ECM (9). Trans-
forming growth factor 1 (TGF-1), a multifunctional cytokine
that controls growth, adhesion, migration, apoptosis, and differ-
entiation of cells (15), is the most important cytokine involved in
fibrogenesis (16). During liver fibrosis, TGF-1 induces trans-
differentiation of quiescent HSCs to myofibroblasts, which, in
turn, produce other cytokines and matrix proteins (17).
It has been suggested that Kupffer cells, activated by the con-
tinuous liver injury caused by HCV infection, are the main source
of TGF-1 (18).However, there have been several reports suggest-
ing that HCV-infected hepatocytes themselves secrete TGF-1
(19–21). Elevation of reactive oxygen species (ROS) in HCV-in-
fected cells was suggested as amechanism for the TGF-1 produc-
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tion inHCV-infected cells (21), andHCV core protein was shown
to be responsible for TGF-1 secretion (19, 20). In contrast, sev-
eral reports have shown that HCV viral protein(s) represses
TGF-1 signaling and/or TGF-1 gene expression (22, 23). For
instance, NS5A protein was shown to inhibit TGF-1 signaling
(22). Moreover, NS5A protein was suggested to inhibit the func-
tion of activating protein 1 (AP-1), a transcriptional activator re-
quired for TGF-1 gene expression (24), by perturbing Ras-ERK
signaling pathway (23).
In this study, we investigated the molecular basis of the fibro-
genesis induced by HCV infection. Particularly, we sought to
identify HCV protein(s), if it exists, that augments TGF-1 pro-
duction by HCV-infected cells. Using molecular biological and
biochemical approaches, we found that HCV-infected hepato-
cytes secrete TGF-1 proteins which are sufficiently high to acti-
vate primaryHSCs.Moreover, high level of TGF-1 was observed
fromHCV-infected liver cells of HCV patients. Our investigation
of the molecular basis of TGF-1 production in HCV-infected
cells revealed that HCV core protein and envelope protein 2 (E2)
participate in elevated TGF-1 production. We also demon-
strated that overproduction of glucose-regulated protein 94
(GRP94) byHCVE2 triggers the signal transduction cascades that
result in the elevated TGF-1 production.
MATERIALS AND METHODS
Cell culture.Huh-7 andHuh-7.5.1 cells were cultured at 37°C in Dulbec-
co’s modified Eagle medium (DMEM; Gibco) supplemented with antibi-
otics (100U/ml of penicillin and 10g/ml of streptomycin) and 10% fetal
bovine serum (FBS; HyClone) in a humidified 5% CO2 environment.
Huh-7 cells containing HCV replicons were grown under the same con-
ditions, with the additional inclusion of the antibiotic G418 (500 g/ml;
AG Scientific) (25). Huh-7 cells expressing HCV E2 or GRP94 were cul-
tured under the same conditions, with the additional inclusion of the
antibiotic hygromycin B (300 g/ml; AG Scientific) (25, 26).
Western blotting.Cells were lysed in passive lysis buffer (Promega).
Proteins in lysates were resolved by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) followed by transfer to nitro-
cellulose membranes (Whatman). Antibodies against GRP94, NS5B,
and -smooth muscle actin (-SMA; Santa Cruz), -actin (ICN), and
TGF-1 (BD Biosciences) were used as primary antibodies. The
monoclonal anti-E2 antibody H52 was a kind gift from Jean Dubuis-
son (University of Lille), and an antibody against core protein was
kindly provided by Ralf Bartenschlager (University of Heidelberg).
Horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG, sheep
anti-mouse IgG (GEHealthcare), and donkey anti-goat IgG (Santa Cruz)
were used as secondary antibodies. Chemiluminescence detection was
performed using WEST-ZOL plus (iNtRON).
siRNA transfection. Knockdown of GRP94 was performed by trans-
fection with a specific small interfering RNA (siRNA) duplex targeting
GRP94 (5=-UGAUGUGGAUGGUACAGUA-3=; Bioneer) using Oligo-
fectamine (Invitrogen) (26). Cells were incubated for 4 h, after which
serum-free medium was replaced with DMEM containing 10% FBS.
qRT-PCR. Total RNA was isolated with TRI-solution (Bioscience
Technology). cDNA synthesis was performed by reverse transcription
reagent (Promega). Quantitative reverse transcription-PCR (qRT-
PCR) was performed with the TaKaRa SYBR Premix EX Taq II proto-
col using an IQ5 multicolor real-time PCR detection system (Bio-
Rad). Sequences of primer pairs for qRT-PCR are as follows: TGF-1,
5=-GGC GAT ACC TCA GCA ACC G-3 and 5=-CTA AGG CGA AAG
CCC TCA AT-3=; HCV, 5=-TCT GCG GAA CCG GTG AGT A-3= and
5=-TCA GGC AGT ACC ACA AGG C-3=; and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), 5=-AGG GCT GCT TTT AAC TCT
GGT-3= and 5=-CCC CAC TTG ATT TTG GAG GGA-3=.
Quantification of TGF-1 by ELISA. Huh-7 cells were seeded in a
100-mmdish and cultured for 12 h. After three washings with phosphate-
buffered saline (PBS), fresh serum-free medium was added. Cells were
then incubated for 24 h, after which culture media were collected and
filtered through a 0.2-m Millipore filter. The amount of secreted
TGF-1 in the culture medium was determined using a human TGF-1
enzyme-linked immunosorbent assay (ELISA) kit (R&DSystems) accord-
ing to the manufacturer’s protocol.
Immunofluorescence assays. The subcellular localization of TGF-1
and HCV core protein was monitored using anti-TGF-1 (BD Biosci-
ences) and anti-core (Affinity Bioreagents) antibodies, respectively. For
immunocytochemistry, HCV-inoculated and uninoculated Huh-7.5.1
cells were fixed with 4% paraformaldehyde (10 min) and then incubated
for 0.5 h in blocking solution containing 1% bovine serum album (BSA)
and 0.1% Tween 20 in PBS to permeabilize cells and block nonspecific
binding of antibodies. Cells were then washed with PBS and incubated at
room temperature for 1 h with primary antibodies. After a washing with
PBS, cells were incubated with secondary antibodies for 1 h.
For immunohistochemistry, paraffin-embedded liver tissue speci-
mens were deparaffinized and rehydrated with xylene and ethanol. Anti-
genic epitopes of samples were exposed by treatment with 10 mM citrate
buffer and heating in amicrowave oven. Sampleswere incubated in block-
ing solution containing 5% horse serum and 0.02% Triton X-100 in Tris-
buffered saline (TBS) at room temperature for 2 h and then incubated
overnight at 4°C with primary antibodies. After a washing with TBS con-
taining 0.01% Triton X-100, the samples were incubated with secondary
antibodies (Invitrogen; Jackson ImmunoResearch) for 2 h. Immuno-
stained samples were observed under an Olympus FV1000 confocal laser
scanning microscope.
Quantification of the imaging data. Images were analyzed using
MetaMorph software. The data from immunocytochemical study of 134
cells and the data from immunohistochemical study of 57 cells were ana-
lyzed using the software. The fluorescence intensities (TGF-1, red; HCV
core, green; andHoechst, blue) of cells weremeasured by the linescan tool
in MetaMorph software. To calculate the level of protein expression in
cells, the sum of fluorescence intensities (TGF-1, red, and HCV core,
green) was divided by the sumofHoechst intensities in the corresponding
cells. The average value of fluorescence intensity in each group was calcu-
lated by dividing the sum of protein level in the group by the number of
cells belonging to the group. The version of MetaMorph used is 7.04r4.
Virus infection and production. In vitro transcription of HCV RNA
(derived from JFH-1) and transfection of RNAs were performed as de-
scribed previously (27). Infectious HCV particles were collected from the
culturemedia of Huh-7.5.1 cells 3 days after transfection with HCVRNA.
The levels of TGF-1 in the media of HCV-infected Huh-7.5.1 cells were
measured 3 weeks after HCV infection using a TGF-1 ELISA kit.
Isolation ofHSCs.PrimaryHSCswere isolated from the livers ofmale
Sprague-Dawley rats according to an establishedmethod (28). Briefly, rat
livers were perfused with Ca2- and Mg2-free Hanks’ balanced salt so-
lution (HBSS) containing 0.025% collagenase B. The resulting liver sus-
pension was incubated at 37°C for 20 min, and HSCs were separated by
centrifugation with an 11.9% Histodenz (Sigma) cushion. The purity of
HSC isolates was greater than 90%, as assessed by fluorescence of an
anti-GFAP (glial fibrillary acidic protein) antibody (Abcam) under UV
excitation (29). Rats were maintained under specific-pathogen-free con-
ditions. All animal procedures were approved by the Animal Care Com-
mittee of POSTECH Biotech Center.
Detection ofHSC activation.HSCswere cultured inDMEMcontain-
ing 3% FBS. After 3 days of incubation, HSCs were transferred to 6-well
plates and cultured for 12 h. The cells were further cultured with serum-
freeDMEM for 24 h. The culturemediawere replacedwith the incubation
media of various cells with or without pretreatment of antibodies for 4 h.
After being cultured for an additional 10 h, HSCs were collected and lysed
with passive lysis buffer (Promega). A recombinant human TGF-1 pro-
tein (R&D Systems) was used as a positive control for activation of HSCs.
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Liver tissue samples.Liver tissue sampleswere donated by liver cancer
patients who provided informed consent, and the utilization of specimens
for this research was authorized by the institutional review boards of the
universities which provided the samples. Tissue sample number 06-
30414N (a nontumor region of a liver cancer patient whowas not infected
with HCV), numbers N1 and N2 (nontumor regions of hepatitis B virus
[HBV] patients), and numbers 375N, 388N, 02-27024N, 03-10521N, and
06-9008N (nontumor regions of HCV patients) were provided by the
Liver Cancer Specimen Bank, supported by National Research Resource
Bank Program of the Korea Science and Engineering Foundation in the
Ministry of Science and Technology. Tissue sample numbers s10-6410-B
and s09-20494 (nontumor regions of HCV patients) were provided by
Ewha Womans University.
RESULTS
HCV infection increases TGF-1 secretion by hepatocytes. To
determine whetherHCV infection affects the secretion of TGF-1
by hepatocytes, wemeasured the amount of TGF-1 in the culture
media of Huh-7.5.1 cells after HCV (JFH-1) infection using a
TGF-1 ELISA. The level of TGF-1 in the culture media from
HCV-infected cells (3 weeks after infection with HCV at a multi-
plicity of infection [MOI] of 0.1)was increased2-fold compared
with that in culture media from mock-infected cells (Fig. 1A).
HCV infection was monitored byWestern blotting of cell extracts
with an antibody against HCV core protein (Fig. 1A).
We also investigated the acute effect of HCV infection on
TGF-1 gene expression by inoculation with a high titer of HCV
(an MOI of 5, ensuring infection of more than 99% of the cells).
Surprisingly, both TGF-1 mRNA and pro-TGF-1 protein (a
precursor of TGF-1) were increased 4-fold in the HCV-in-
fected cells at 2 days after infection (Fig. 1B and C, respectively).
The results indicated that HCV infection stimulated the produc-
tion and secretion of TGF-1 by hepatocytes.
TGF-1 protein levels are high in HCV-infected cells and in
neighboring cells. TGF-1 levels in individual hepatocytes in-
fected with JFH-1 were investigated using fluorescence immuno-
cytochemistry. HCV-infected cells were detected using an anti-
body against HCV core protein, and intracellular TGF-1 was
stained using a specific anti-TGF-1 antibody.Much higher levels
of TGF-1 (red) were observed in HCV-infected cells (green)
than in uninfected cells (compare Fig. 2A-1 and A-2). In order to
compare the levels of TGF-1 in individual cells in the HCV-
inoculated sample, we further analyzed the immunocytochemis-
try data shown in Fig. 2A-2 using MetaMorph software (Fig. 2B).
We classified HCV-inoculated cells into three groups: (i) HCV-
infected cells, which showed high levels of HCV core protein (Fig.
2B-1); (ii) uninfected neighboring cells, which showed undetect-
able levels of HCV core protein but were in direct contact with
HCV-infected cells (Fig. 2B-2); and (iii) uninfected nonneighbor-
ing cells, which did not show HCV core protein and were not in
contact with HCV-infected cells (Fig. 2B-3). The intensity of sig-
nals emitted by HCV core (green), TGF-1 (red), and Hoechst
(blue) along transects through individual cells, indicated by red
lines in the left images in Fig. 2B, are depicted in the traces in the
right images in Fig. 2B. These data indicate that high levels of
TGF-1 proteins were present in the cytoplasm of HCV-infected
cells and that TGF-1 protein was not colocalized with HCV core
proteins even though both proteins were found in the cytoplasm.
Statistical analyses of TGF-1 protein in individual cells (Tables 1
and 2) showed that the average amount of TGF-1 protein in
HCV-infected cells was more than 20-fold higher than that in
uninoculated cells (Table 1) and that the average amounts of
TGF-1 protein in uninfected cells neighboring HCV-infected
cells and in uninfected nonneighboring cells were 5.6- and 2.8-
fold higher than that inmock-inoculated cells, respectively (Table
1). Many HCV-infected cells showed more than 30-fold-higher
relative TGF-1 levels (RTLs) (Table 2), whereas none of the un-
FIG 1 HCV infection induces TGF-1 secretion. (A) TGF-1 levels in the
culturemedia ofHuh-7.5.1 cells, infectedwithHCV (JFH-1) ormock infected,
were examined by ELISA. Huh-7.5.1 cells were infected with HCV (MOI, 0.1)
andmaintained for 3 weeks; then the same numbers of HCV-infected cells and
mock-infected cells (7 105) were seeded on 100-mm dishes and cultured for
12 h. The media were changed to DMEM without FBS, and the cells were
cultured for an additional 24 h. Culture media were collected and analyzed by
ELISA after being filtered through a 0.2-m-pore filter. Data are presented as
means and standard deviations (bars and error bars, respectively) from three
independent experiments. HCV infections were confirmed by Western blot-
ting for HCV core protein. The extracts from mock-infected (lane 1) and
HCV-infected (lane 2) Huh-7.5.1 cells were resolved by SDS-PAGE on 12%
gels and analyzed by Western blotting with antibodies against HCV core pro-
tein and -actin (used as a loading control). (B) HCV infection induces
TGF-1 mRNA production. Huh-7.5.1 cells were inoculated with HCV (JC1
E2-Flag; MOI, 5) and cultivated for 2 days. The amounts of TGF-1mRNA in
the HCV-infected (lane 2) and mock-infected cells were measured by qRT-
PCR using the total RNAs isolated by TRI-solution method (Bioscience Tech-
nology). The amount of TGF-1 mRNA was normalized by that of GAPDH
mRNA. The relative amounts of TGF-1mRNA in theHCV-infected cells and
the mock-infected cells are depicted. The experiments were performed three
times, and the means and standard deviations are depicted by bars and error
bars, respectively. (C) HCV infection augments production of pro-TGF-1 (a
precursor of TGF-1) and GRP94. Huh-7.5.1 cells were inoculated with HCV
(JC1 E2-Flag; MOI, 5) and cultivated for 2 days (lane 2) or 4 days (lane 4).
Mock-infected cells were cultivated for 2 days (lane 1) or 4 days (lane 3) as
negative controls. The amounts of HCV E2, pro-TGF-1, GRP94, and-actin
proteins were monitored by Western blotting analyses using corresponding
antibodies. Asterisks in the figures indicate P values: *, P 0.05; **, P 0.001.
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infected cells in the HCV-inoculated sample showed RTLs greater
than 20-fold (Table 2). The relationship between HCV infection
and TGF-1 production was evaluated by calculating the Pearson
correlation coefficient from theMetaMorph analysis results (RTL
values) shown in Table 2. The Pearson correlation coefficient
value (0.88) indicates thatHCV infection andTGF-1 production
are highly correlated. The biochemical and immunocytochemical
results indicate that TGF-1 expression was augmented in HCV-
FIG 2 TGF-1 expression is augmented in HCV-infected cells and their neighboring cells. (A) Huh-7.5.1 cells were inoculated or mock inoculated with HCV
(JFH-1; MOI, 0.1) and then cultivated for 3 days. The uninoculated (A-1) and HCV-inoculated (A-2) samples were stained with Hoechst 33342 (blue) and
immunostained with antibodies against HCV core (green) and TGF-1 (red) proteins. Representative fluorescence microscopic images of TGF-1, HCV core
protein (Core), and nuclei (Hoechst) are shown. Merged images are also presented. Scale bar	 10 m. (B) Quantitative analyses of fluorescence intensities of
TGF-1 and HCV core protein signals in HCV-infected cells (B-1), uninfected neighboring cells (B-2), and nonneighboring cells (B-3) in HCV-inoculated
samples and uninfected cells in uninoculated samples (B-4) were performed using MetaMorph software.
HCV E2 Enhances TGF-1 Secretion
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infected cells. Moreover, the elevated RTL of uninfected non-
neighboring cells compared with the RTL of uninoculated, unin-
fected cells suggests that one or more cytokines secreted from
HCV-infected cells stimulated expression of TGF-1 in HCV-
uninfected cells in the same culture dish.
HCV-infected liver cells of HCV patients express high levels
of TGF-1. We next investigated whether HCV infection results
in overproduction of TGF-1 protein in the liver cells of HCV
patients as it does in the in vitro culture system. For this purpose,
we performed Western blot analysis with nontumor regions of
liver tissues from liver cancer patients with (Fig. 3A, lanes 2 to 6)
or without (lane 1 in Fig. 3A) HCV infection. Clinical back-
grounds of the specimens are summarized inMaterials andMeth-
ods. TGF-1 protein was highly expressed in the nontumor re-
gions of liver tissues of HCV patients. On the other hand, TGF-1
protein was not detectable from the nontumor region of a liver
tissue of a liver cancer patient who was not infected with HCV
(Fig. 3A, compare lane 1 with lanes 2 to 6).
In order to investigate TGF-1 expression in the individual
cells of HBV and HCV patients’ liver tissues, we performed im-
munohistochemical studies using nontumor regions of liver tis-
sues of HBV and HCV patients (Fig. 3C). To monitor HCV-in-
fected cells and TGF-1 levels, we used antibodies against HCV
core protein (green) and TGF-1 (red), respectively. As expected,
core-positive signals were detected in HCV patients’ tissues (Fig.
3C, panels j, n, and r) but not in HBV patients’ tissues (Fig. 3C,
panels b and f). Consistent with in vitro HCV culture system re-
sults, HCV-infected cells in liver tissue from patients expressed
high levels of TGF-1 (Fig. 3C, panels i to t). In contrast, TGF-1
signals were much weaker in cells negative for HCV core protein
(noninfected cells) (Fig. 3C, panels i to t) and were very weak in
cells from HBV patients’ tissues (Fig. 3C, panels a to h). We esti-
mated the amounts of TGF-1 and HCV core proteins in the
individual cells of HBV and HCV patients using the immunohis-
tochemical data shown in Fig. 3C with MetaMorph software sim-
ilarly to the cases with Fig. 2B and Tables 1 and 2. In this analysis,
we classified the liver cells into three groups: group 1 consisted of
HBV-infected cells, which were in the nontumor regions of HBV
patients’ liver tissues; group 2 consisted of HCV-infected cells,
which were in the nontumor regions of HCVpatients’ liver tissues
and showed high levels of HCV core protein; and group 3 con-
sisted of uninfected cells which were in the nontumor regions of
HCV patients’ liver tissues but did not show HCV core protein.
The average amount of TGF-1 protein in group 2 was14-fold
higher than that in group 1. We further investigated the relation-
ship between HCV infection and TGF-1 production by calculat-
ing the Pearson correlation coefficient using the estimated
amounts of TGF-1 andHCV core proteins in the immunohisto-
chemical data. The Pearson correlation coefficient (0.94) indicates
that HCV infection and TGF-1 production were very highly cor-
related. These results suggest that one or more HCV proteins
stimulated the production and/or stabilization of TGF-1 protein
in the HCV-infected cells of liver tissue from HCV patients.
HCV core and E2 proteins enhance TGF-1 secretion by
HCV replicon-containing cells. Results from our in vitro HCV
culture system and our investigation of patients’ liver tissues
showed that HCV-infected hepatocytes produced more TGF-1
protein than uninfected cells (Fig. 1 to 3). To understand the mo-
lecular basis of the elevated TGF-1 expression in HCV-infected
cells, we sought to identify the HCV protein(s) responsible for the
overproduction of TGF-1. In order to mimic HCV infection, we
used various HCV replicons expressing various structural pro-
teins of HCV (core, E1, and E2). The replicons Core(UAA),
E1(UAA), and E2(UAA) direct expression of core, core plus E1,
TABLE 2 Numbers of cells showing various levels of TGF-1 in the
different groupsa
Sample type Cell category
Relative TGF-1
level (RTL) Cell no.
HCV-inoculated
sample
HCV-infected cells Subtotal 87
40 RTL 5
30 RTL 40 12
20 RTL 30 26
10 RTL 20 29
5 RTL 10 11
RTL 5 4
Uninfected neighboring
cells
Subtotal 12
40 RTL 0
30 RTL 40 0
20 RTL 30 0
10 RTL 20 1
5 RTL 10 5
RTL 5 6
Uninfected nonneighboring
cells
Subtotal 25
40 RTL 0
30 RTL 40 0
20 RTL 30 0
10 RTL 20 0
5 RTL 10 1
RTL 5 24
Uninoculated Uninfected cells Subtotal 10
40 RTL 0
30 RTL 40 0
20 RTL 30 0
10 RTL 20 0
5 RTL 10 0
RTL 5 10
Total 134
a The amounts of TGF-1 proteins in the cells were estimated by MetaMorph software
using the immunocytochemical data shown in Fig. 2B and data not shown (total of 134
cells). The relative amount of TGF-1 proteins (RTL) in the cells was calculated by
setting the average amount of TGF-1 proteins in the uninoculated, uninfected cells as
1.
TABLE 1 Relative amounts of TGF-1 protein in various groups of
cellsa
Sample type Cell category
Relative amt
of TGF-1
(avg)
HCV-inoculated
sample
HCV-infected cells 21.8
Uninfected neighboring
cells
5.6
Uninfected nonneighboring
cells
2.8
Uninoculated
sample
Uninfected cells 1.0
a The amounts of TGF-1 proteins in the cells were estimated by MetaMorph software
using the immunocytochemical data shown in Fig. 2B and immunocytochemical data
not shown (total of 134 cells). The amount of TGF-1 in the uninoculated, uninfected
cells was set to 1 in normalization.
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and core plus E1 plus E2, respectively, together with nonstructural
proteins NS3 to NS5A, as described by Lee et al. (25) (Fig. 4A); the
replicon 2 C399T expresses only nonstructural proteins. The
replicon 2 C399T showed reduced levels of TGF-1 protein in
the culture media compared to the culture media of control
Huh-7 cells (Fig. 4B, compare bar 2with bar 1). This indicates that
nonstructural protein(s) of HCV inhibits expression of TGF-1
by host cells (see Discussion). Huh-7 cells containing replicons
Core(UAA) and E1(UAA) restored TGF-1 levels to values com-
parable to those in control Huh-7 cells (Fig. 4B, compare bars 3
and 4 with bar 1). This result indicates that HCV core contributes
to secretion of TGF-1. This result is consistent with a previous
report suggesting that the HCV core augments TGF-1 through
ROS generation (21). Interestingly, TGF-1 levels in the media
were greatly increased by the replicon E2(UAA), which produces
HCV E2 (Fig. 4B, lane 5). This suggests that HCV E2 augments
TGF-1 expression via an unknown mechanism. To determine
whether HCV E2 is capable of enhancing TGF-1 expression
FIG 3 HCV-infected liver cells of HCV patients express high levels of TGF-1 protein. (A) Protein levels of HCV core, TGF-1, GRP94, and -actin were
analyzed by Western blotting using nontumor regions of liver tissues from liver cancer patients with (lanes 2 to 6) or without (lane 1) infection of HCV. (B)
Pearson correlation coefficients of protein levels ofHCV core, TGF-1, andGRP94 in the liver tissues were calculated by using the protein band intensities shown
in panel A. (C) Nontumor regions of liver tissues from HBV patients (N1 and N2) and HCV patients (s09-20494 and s10-6410-B) were stained with Hoechst
33342 (blue) or immunostained with antibodies against HCV core (green) and TGF-1 (red) proteins. Representative fluorescence microscopic images of
TGF-1, HCV core protein (Core), and nuclei (Hoechst) are shown. Merged images are also presented. Scale bar	 10 m.
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without the help of other HCV proteins, we used a Huh-7 cell line
that expresses HCV E2. HCV E2-expressing Huh-7 cells exhibited
greatly increased TGF-1 secretion (Fig. 4D), suggesting that
HCV E2 alone is able to mediate increased TGF-1 production.
GRP94 activity is required for HCV E2-mediated overpro-
duction of TGF-1. We investigated the mechanism underlying
TGF-1 overproduction byHCVE2. Previously, we reported that
HCV E2 activates the nuclear factor 
B (NF-
B) signaling path-
way through overproduction of GRP94, which is a molecular
chaperone that functions in processing and transporting secretory
proteins (26). Notably, ectopic expression of HCV E2 in Huh-7
cells strongly augmented the expression of GRP94 but did not
affect the expression of HSP90, a cytosolic homologue of GRP94
(Fig. 4E). In addition, overproduction of GRP94 was observed in
the Huh-7.5.1 cells infected with HCV (Fig. 1C and 5E) and the
liver tissues of HCV patients (Fig. 3A).
We next examined whether GRP94 overproduction triggered
by HCV E2 contributed to the augmented TGF-1 secretion. In-
deed, GRP94-overproducing cells exhibited elevated TGF-1 se-
cretion in the absence of E2 protein (Fig. 4D, bar 3). Moreover,
depletion of GRP94 using a small interfering RNA (siRNA) re-
duced TGF-1 secretion by Huh-7 cells ectopically expressing
HCV E2 (Fig. 5A, bar 4) or GRP94 (Fig. 5B, bar 4). Notably,
TGF-1 secretion by control Huh-7 cells was reduced by deple-
tion of GRP94 (Fig. 5A and B, bars 2), indicating that the rather
high basal secretion of TGF-1 from control Huh-7 cells is attrib-
utable, at least in part, to the high level of GRP94 in these cells.
Depletion of GRP94 by an siRNA against GRP94 reduced
TGF-1 secretion by Huh-7 cells containing HCV E2(UAA) rep-
licon (data not shown). Also, depletion of GRP94 reduced pro-
duction of pro-TGF-1 by HCV-infected cells (Fig. 5E). More-
over, strong relationships among HCV infection, GRP94, and
FIG 4 HCV E2 augments secretion of TGF-1. (A) Schematic diagram of HCV replicons used in this study. Replicon 2 C399T expresses only HCV
nonstructural proteins NS3 to NS5B. Replicons Core(UAA), E1(UAA), and E2(UAA) express core, core plus E1, and core plus E1 plus E2, respectively, in
addition to the nonstructural proteins NS3 to NS5B (25). (B) TGF-1 levels in culture media of Huh-7 cells containing various HCV replicons were examined
by ELISA. Replicon-containing cells (7 105) were seeded on 100-mm dishes and cultured for 12 h. The media were replaced with serum-free DMEM, and the
cells were cultured for an additional 24 h. Culture media were collected and analyzed by ELISA after being filtered through a 0.2-m-pore filter. (C) The levels
ofHCVNS5B, E2, and core proteins in control Huh-7 cells (lane 1) andHuh-7 cells containing replicon2C399U (lane 2), Core(UAA) (lane 3), E1(UAA) (lane
4), or E2(UAA) (lane 5) were determined by Western blotting analyses with anti-NS5B, anti-E2, anti-core, and anti--actin antibodies. (D) TGF-1 levels in
culture media of control Huh-7 cells (hygromycin-selected cells) and Huh-7 cells expressing HCV E2 or GRP94 were examined by ELISA, as described for panel
B. (E) Levels of HSP90, GRP94, HCV E2, and -actin proteins in control cells (lane 1), E2-overproducing cells (lane 2), and GRP94-overproducing cells (lane 3)
were analyzed byWestern blotting with anti-HSP90, anti-GRP94, anti-E2, and anti--actin antibodies. All data are presented as means and standard deviations
(bars and error bars, respectively) from three independent experiments.
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TGF-1 in the human liver are also indicated by the high Pearson
correlation coefficients among these items (Fig. 3B). Taken to-
gether, these data strongly suggest that HCV E2 triggers expres-
sion of TGF-1 through overproduction of GRP94.
We further investigated the role of GRP94 activity in TGF-1
secretion using 17-allylamino-demethoxygeldamycin (17-AAG),
an inhibitor of GRP94 that blocks the activities of GRP94 and
HSP90. Treatment with 17-AAG (250 nM) reduced secretion of
TGF-1 protein by control Huh-7 cells as well as Huh-7 cells
ectopically expressing either E2 or GRP94 (Fig. 5F, bars 2, 4, and
6). Moreover, treatment of 17-AAG (250 nM) reduced TGF-1
secretion by Huh-7 cells containing the HCV E2(UAA) replicon
(data not shown). These results indicate that GRP94 activity is
required for high levels of TGF-1 secretion by HCV-infected
cells.
Activation of NF-B is required for the enhanced secretion
of TGF-1 protein by HCV-infected hepatocytes. Previously,
we reported that GRP94 overproduction by HCV infection en-
hances the expression of anti-apoptotic proteins in an NF-
B-
dependent manner (26). Moreover, Lin et al. reported that
TGF-1 production is increased by HCV infection via NF-
B
activation (21). On the basis of these previous observations, we
investigated whether the augmented secretion of TGF-1 pro-
teins by HCV E2 is mediated by NF-
B activation. To this end,
we examined the effect of the IKK/ inhibitor Bay 11-7082 on
TGF-1 secretion by Huh-7 cells overproducing HCV E2 or
GRP94 (Fig. 6). Treatment with Bay 11-7082 decreased
TGF-1 secretion by both E2- and GRP94-overproducing cells
(Fig. 6). Moreover, treatment with Bay 11-7082 decreased
TGF-1 secretion by Huh-7 cells containing the HCV
FIG 5 Overproduction of GRP94 is required for E2-dependent TGF-1 pro-
duction. (A) Effect of GRP94 knockdown on the secretion of TGF-1 from
control Huh-7 cells (bars 1 and 2) andHuh-7 cells ectopically expressingHCV
E2 (bars 3 and 4). Cells were seeded in 12-well plates at 4  104 cells/well,
cultured for 12 h, and then transfected with an siRNA against GRP94 using
Oligofectamine and cultured for 48 h. After culturing of cells in serum-free
media for an additional 24 h, TGF-1 levels in culturemediawere examined by
ELISA. (B) The effect of GRP94 knockdown on the secretion of TGF-1 from
theHuh-7 cells ectopically expressingGRP94 (bars 3 and 4) was determined as
described for panel A. (C and D) GRP94 siRNA knockdown efficiencies were
monitored byWestern blotting analyses. (C) Control (lanes 1 and 2) andHCV
E2-overproducing (lanes 3 and 4) Huh-7 cells described for panel A were
analyzed by Western blotting with anti-GRP94, anti-HCV E2, and anti--
actin antibodies. (D) Control (lanes 1 and 2) and GRP94-overproducing
(lanes 3 and 4) Huh-7 cells described for panel B were analyzed by Western
blotting with anti-GRP94 and anti--actin antibodies. (E) Effect of GRP94
knockdown on the production of pro-TGF-1 by HCV-infected cells. Huh-
7.5.1 cells were inoculated with HCV (JC1; MOI, 0.1) and cultivated for 4
weeks. HCV-infected andmock-infected cells were seeded on 12-well plates (5
 104 cells/well) and cultivated for 12 h, and then the cells were transfected
with an siRNA against GRP94 using Oligofectamine. The cells were further
cultivated for 72 h, and then the levels of HCV core, GRP94, pro-TGF-1, and
-actin proteins in the cells were examined by Western blotting using corre-
sponding antibodies. (F) Effect of the GRP94 inhibitor 17-AAG on the pro-
duction of TGF-1 by Huh-7 cells ectopically expressing GRP94 or HCV E2.
Cells were seeded on 12-well plates at 5 104 cells/well and cultured for 12 h.
After treatment with 17-AAG (250 nM) in DMEM containing 10% FBS for 12
h, cells were cultured in serum-free DMEM with 17-AAG (250 nM) for an
additional 24 h. The culture media were collected, filtered through a 0.2-m-
pore filter, and analyzed by ELISA. All data are presented as means and stan-
dard deviations (bars and error bars, respectively) from three independent
experiments.
FIG6 Activation ofNF-
B is required for E2-dependent TGF-1 production.
Effects of the NF-
B inhibitor Bay 11-7082 on the production of TGF-1 by
Huh-7 cells ectopically expressing HCV E2 or GRP94 were analyzed. Cells
were seeded on 12-well plates at 5 104 cells/well and cultured for 12 h.Media
were replaced with DMEM containing 10% FBS and Bay 11-7082 (5M), and
cells were incubated for 12 h. After culturing of cells in serum-free media
containing Bay 11-7082 (5 M) for an additional 24 h, TGF-1 levels in cul-
ture media were examined by ELISA. Data are presented as means and stan-
dard deviations (bars and error bars, respectively) from three independent
experiments.
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E2(UAA) replicon (data not shown). These results indicate that
NF-
B activation is involved in HCV E2-dependent TGF-1
secretion, although additional research, currently ongoing in
our laboratory, will be necessary to establish the mechanistic
details.
TGF-1protein secretedbyHCV-infected cells activates pri-
maryHSCs.Activated HSCs play a key role in liver fibrosis, and
TGF-1 is the major cytokine involved in activating HSCs.
Accordingly, we investigated whether TGF-1 protein secreted
by HCV-infected cells and HCV E2-overproducing cells is suf-
ficient to activate HSCs. For this purpose, we isolated rat pri-
mary HSCs using a perfusion and collagenase digestion
method (28). Using these HSCs, we examined the effects of
culture media from HCV-infected cells or HCV E2-overpro-
ducing cells on HSC activation by Western blotting for
-smooth muscle actin (-SMA), an indicator of HSC activa-
tion (30). Treatment with culture media (5-fold diluted) from
HCV-infected Huh-7.5.1 cells increased -SMA in primary
HSCs about 3-fold compared with that in primary HSCs
treated with control uninfected Huh-7.5.1 cell culture media
(Fig. 7A, compare lane 2 with lane 1). The level of primary HSC
activation was comparable with the activation of the cells by
stimulation with TGF-1 protein at a final concentration of 2
ng/ml (Fig. 7A, lane 3). Treatment with culture media from
Huh-7 cells expressing HCV E2 (5-fold diluted) also activated
primary HSCs (Fig. 7A, lanes 4 to 6).
In order to test whether TGF-1 protein secreted by Huh-7
cells overproducing HCV E2 is the major cytokine that activates
HSCs, we examined the effect of a TGF-1-neutralizing antibody.
Addition of a TGF-1-neutralizing antibody to culture media
from both control cells and HCV E2-overproducing cells reduced
the levels of -SMA in primary HSCs (Fig. 7B). Importantly, the
level of-SMAwas reduced to the same level as in the control cells
after treatment of the TGF-1 antibody (Fig. 7B and C). This
clearly demonstrates that TGF-1 is the key cytokine activating
HSCs by the HCV E2. Taken together, these results indicate that
FIG 7 TGF-1 secreted by HCV E2-overproducing cells activates primary HSCs. (A) HSCs isolated from Sprague-Dawley rats were incubated in DMEM
containing 3% FBS for 3 days. HSCs were then seeded on 6-well plates at 8 104 cells/well and cultured for 12 h. After culturing of cells for 24 h in serum-free
media, media were replaced with culture media from control Huh-7.5.1 cells (lane 1) or HCV-infected Huh-7.5.1 cells (lanes 2) or with serum-free media
supplemented with 2 ng/ml of recombinant human TGF-1 (lane 3), and HSCs were incubated for an additional 10 h. HSCs were then harvested, and levels of
-SMA (a marker of HSC activation) and eukaryotic initiation factor 3B (eIF3B; control) were monitored by Western blotting. Similar experiments were
performed using culture media from control Huh-7 cells (lane 4), HCV E2-overproducing cells (lane 5), and serum-free media supplemented with 2 ng/ml of
recombinant human TGF-1 (lane 6). The relative amounts of -SMA in cells normalized to those of eIF3B are depicted at the top. (B) Isolated HSCs were
incubated in DMEM containing 3% FBS for 3 days, after which they were seeded on 6-well plates at 5 104 cells/well and cultured for 12 h. After culturing of
cells for 24 h in serum-free media, media were replaced with culture media from control Huh-7 cells (lanes 2 and 4) or HCV E2-overproducing cells (lanes 1 and
3), and cells were incubated for an additional 10 h. Culture media were pretreated with either a control mouse antibody (lane 1 and 2) or neutralizing
anti-TGF-1 antibody (lanes 3 and 4) at 4°C for 4 h before culturing of HSCs. The cells were harvested, and levels of -SMA and eIF3B were monitored by
Western blotting. The relative amounts of -SMA in cells normalized to those of eIF3B are depicted on top of the panel. The same experiment was performed
independently two times. (C) Relative amount of -SMA in HSCs from panel B, depicted graphically.
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the amount of TGF-1 protein produced by HCV infection is
sufficient to activate HSCs.
DISCUSSION
HCV infection is closely associated with liver fibrosis, a major risk
factor related to fatal liver diseases, such as liver cirrhosis andHCC
(31). TGF-1 is the most important cytokine involved in trigger-
ing liver fibrosis. It has been suggested that Kupffer cells and liver-
infiltrating lymphocytes are the major sources of TGF-1 protein
(32, 33). However, a number of reports have suggested that HCV-
infected hepatocytes could be the original source of TGF-1 pro-
tein (21, 34, 35). In this study, we monitored the effect of HCV
infection on the production of TGF-1 in individual hepatocytes
for the first time using an immunocytochemical method. We
found that HCV-infected cells expressed the highest levels of
TGF-1 but that cells neighboring HCV-infected cells also pro-
duced high levels of TGF-1 (Fig. 2 and Tables 1 and 2). More-
over, TGF-1 levels in uninfected, nonneighboring cells on the
same culture dish were higher than those in cells on an uninocu-
lated culture dish. These results indicate that one or more HCV
protein(s) triggers the production of TGF-1 in HCV-infected
cells and further suggest that protein(s) secreted from HCV-in-
fected cells acts in a paracrine manner to induce TGF-1 produc-
tion in uninfected cells on the same dish (see below). Importantly,
high levels of TGF-1 proteinwere also observed inHCV-infected
hepatocytes in liver tissue from HCV patients (Fig. 3), suggesting
that the strong expression of TGF-1 in HCV-infected hepato-
cytes occurs under physiological conditions.
Elevated production of TGF-1 mRNA and pro-TGF-1 pro-
tein was observed as early as 2 days after infection with HCV (Fig.
1B and C). On the other hand, a detectable increase of TGF-1
proteins secreted in the media was observed only at 3 weeks after
infection with HCV (Fig. 1A). The delayed secretion of TGF-1
may be attributable in part to the complex processes of proteolytic
cleavage and secretory pathway of TGF-1 (36, 37). Interestingly,
it was reported that HCV infection reduces the expression of pro-
protein convertase subtilisin/kexin type 9 (PCSK9) (38), which is
also known tomediate the proteolytic processing of TGF-1 (39).
Therefore, it is likely that the secretion of TGF-1 is modulated
after the production of pro-TGF-1 by HCV infection. The regu-
latory mechanism of TGF-1 secretion from the HCV-infected
cells remains to be elucidated.
In an effort to understand the molecular basis of TGF-1 pro-
duction by HCV infection, we analyzed the effects of HCV struc-
tural proteins on TGF-1 production. To minimize artifacts re-
sulting from ectopic production of a heterologous gene in a cell
line, we used various HCV replicon-containing cells that mimic
the HCV infection state of hepatocytes. These replicons direct
expression of nonstructural proteins NS3 to NS5B and a limited
number of HCV structural proteins (none, core, core plus E1, or
core plus E1 plus E2) (Fig. 4A). To our surprise, TGF-1 produc-
tion byHuh-7 cells was reduced in the presence of the subgenomic
replicon expressing only the nonstructural proteins NS3 to NS5B
(Fig. 4B). This indicates that one or more of the HCV nonstruc-
tural proteins inhibit TGF-1 production. We speculate that
NS5A is a potential candidate inhibitory viral protein, since it
inhibits expression of the transcription activator AP-1 (23), which
is responsible for promoting TGF-1 expression. NS5A may also
contribute to TGF-1 reduction by inhibiting TGF- receptor
function through protein-protein interactions (22).
The reduced production of TGF-1 by HCV nonstructural
protein(s) was restored to the original level by coexpression of
nonstructural proteins with core protein or core plus E1 (Fig. 4B).
This indicates that HCV core protein augments TGF-1 produc-
tion, consistent with previous reports by Shin et al. (19) and Tani-
guchi et al. (20). The generation of ROS by core protein could be
the underlying mechanism of TGF-1 production by the core
protein (21).
Notably, we found thatHCVE2 further enhanced the secretion
of TGF-1 from the cells containing the HCV replicon E2(UAA),
which expresses E2 in addition to core and E1 proteins and non-
structural proteins (Fig. 4B). This suggests that HCV E2mediated
the enhanced TGF-1 production by HCV-infected cells. To test
this, we generated a Huh-7 cell line ectopically expressing only E2
and found that expression of HCV E2 is sufficient to trigger over-
production of TGF-1. To elucidate the mechanism underlying
E2-mediated TGF-1 production, we investigated the role of
GRP94, since E2 is known to trigger overproduction of GRP94
(26). Several lines of evidence indicated that GRP94 is responsible
for the E2-mediated TGF-1 production: (i) ectopic expression of
GRP94 in Huh-7 cells induced production of TGF-1 (Fig. 4D),
(ii) knockdown of GRP94 reduced production of TGF-1 by both
control Huh-7 cells and E2-expressing Huh-7 cells (Fig. 5A), (iii)
TGF-1 production was reduced by a chemical inhibitor (17-
AAG) of GRP94 (Fig. 5F), (iv) depletion of GRP94 reduced pro-
duction of pro-TGF-1 by HCV-infected cells (Fig. 5E), and (v)
the levels of GRP94 and TGF-1 were highly correlated in the
human liver tissues (Fig. 3A and B). On the basis of these obser-
vations, we conclude that HCV E2 augments TGF-1 production
by triggering overproduction of GRP94.
It is not fully understood how the overproduction of GRP94
induces TGF-1 expression. However, we previously showed that
overproduction of GRP94 activates the NF-
B signaling pathway,
which results in production of anti-apoptotic proteins (26). In this
study, using an inhibitor of NF-
B signal transduction, we dem-
onstrated that NF-
B activation is involved in mediating TGF-1
expression, providing a clue to the molecular mechanism linking
GRP94 to TGF-1 production (Fig. 6). Consistent with this result,
it has been shown that NF-
B activation is involved in TGF-1
production in hepatocytes (21).Moreover, Chiao and colleagues
have shown that NF-
B activation enhances AP-1 activation in
murine embryonic fibroblasts (MEF) (40), and Sullivan and
coworkers have suggested that increased c-Fos expression and
c-Jun phosphorylation triggered by tumor necrosis factor al-
pha (TNF-) constitute the mechanism underlying TNF-–
induced TGF-1 expression in lung fibroblasts (24). c-Jun and
c-Fos proteins are components of AP-1 (24), which is a transcrip-
tion factor that enhances TGF-1 expression (41). Indeed, we also
observed that HCV E2-mediated overproduction of GRP94 trig-
gers TNF- secretion through the activation of NF-
B (unpub-
lished data) and that treatment ofHuh-7 cells withTNF- induces
TGF-1 production (data not shown). Moreover, we have found
that TGF-1 secretion by Huh-7 cells expressing E2 or GRP94 is
decreased by addition of a TNF--neutralizing antibody to the
culture media (data not shown). Therefore, we speculate that E2
in HCV-infected cells indirectly induces secretion of TNF-, and
this cytokine, in turn, triggers TGF-1 production by HCV-in-
fected cells and neighboring cells in an autocrine or paracrine
manner.
What would be the physiological consequence of TGF-1 pro-
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duction by HCV-infected hepatocytes apart from its role in the
pathogenesis of hepatic fibrosis? Studies have revealed that pa-
tients with chronic HCV have higher levels of regulatory T (Treg)
cells—which play important roles in immunological tolerance
and viral persistence (42, 43)—in the peripheral blood compared
with healthy control subjects or patients whose HCV infection
spontaneously resolves (44, 45). Moreover, Treg cells have been
shown to suppress the proliferation of HCV-specific cytotoxic T
lymphocytes during persistentHCV infection (46, 47). There have
also been reports that HCV-infected hepatocytes directly induce
the development of Treg cells, which contribute to the impaired
host T-cell responses (34, 48). Considering that TGF- plays a
pivotal role in the generation of Treg cells from precursor cells
(49), we speculate that TGF-1 produced by HCV core and E2
proteins contributes to the induction of Treg cells and the induc-
tion of immune tolerance against the HCV proteins.
In conclusion, as a result of our efforts to elucidate the molec-
ular basis of the pathogenesis of hepatic fibrosis caused by HCV
infection, we have uncovered a novel mechanism of TGF-1 in-
duction.We found that the cellular proteinGRP94, which directly
interacts with HCV E2, plays an important role in TGF-1 induc-
tion, suggesting that GRP94 is a potential target for the develop-
ment of drugs that prevent hepatic fibrosis caused by HCV infec-
tion. Moreover, such a GRP94-inhibiting drug would also likely
boost immunity against HCV infection by blocking the induction
of Treg cells, which direct the immune tolerance against HCV.
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